Iris Unipi Prodmetadata only
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer
angiogenesis, biomarkers, gastric cancer, ramucirumab, svegfr-2, vegf-a, vegf-d
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 185551
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.